Telix announced that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F-18 or ¹⁸F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).

Pixclara is a radioactive diagnostic drug indicated for use with positron emission tomography (PET) to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older.

UCSF Innovation Ventures congratulates Radiologist Thomas Hope, MD, on this milestone approval.

Find out more